Roche Holding AG (RHHBY)
OTCMKTS: RHHBY · Delayed Price · USD
39.27
-0.05 (-0.13%)
Jul 19, 2024, 3:59 PM EDT - Market closed
Roche Holding AG Revenue
In the year 2023, Roche Holding AG had annual revenue of 60.44B CHF.
Revenue (ttm)
60.44B CHF
Revenue Growth
-8.16%
P/S Ratio
3.73
Revenue / Employee
583,379 CHF
Employees
103,605
Market Cap
253.34B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | 3.01B | 4.80% |
Dec 31, 2021 | 62.80B | 4.48B | 7.68% |
Dec 31, 2020 | 58.32B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRHHBY News
- 25 minutes ago - Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs? - Forbes
- 4 days ago - HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer - Business Wire
- 4 days ago - New data for Roche's Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions - GlobeNewsWire
- 4 days ago - New Data for Genentech's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions - Business Wire
- 4 days ago - Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study - Business Wire
- 4 days ago - Roche's Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study - GlobeNewsWire
- 4 days ago - Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise - Investopedia
- 4 days ago - Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk - Market Watch